In the latest Psoriasis Review IPC's bi-annual review of the latest news in the field of psoriasis. read the latest issue
Psoriasis News Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis8/20/2019 10:08:00 AMEli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO). FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease8/6/2019 11:36:00 AMCelgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. Updated Disease Classification System Adopted by the World Health Organization8/1/2019 7:19:00 AMOn 25 May 2019, the World Health Assembly officially adopted the eleventh revision of the International Classification of Diseases (ICD-11). The ICD-11 will come into effect on 1 January 2022. FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)8/1/2019 7:09:00 AMSamsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab)i , for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. Please see full indications and Boxed Warning for HADLIMA™, below. More News